The biopharma business develops, produces and markets prescription drugs for the therapeutic areas of Neurodegenerative Diseases, Oncology, Fertility, Endocrinology, CardioMetabolic Care and General Medicine.
In oncology, we are focusing on therapeutic options that systematically target the tumor. The key is finding the right combination. This refers both to the targets of a therapy in the disease process and to the combination possibilities with standard therapies such as radiation or chemotherapy.
We offer a comprehensive range of therapeutic options for cardiovascular diseases, diabetes and thyroid diseases, thus making a significant contribution to effective treatment of often complex symptoms.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.
To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone. Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.